ESTRADIOL AND NORETHINDRONE ACETATE
Clinical safety rating: avoid
CYP3A4 inducers can decrease efficacy Can cause thromboembolic disorders.
Estradiol is an estrogen that binds to estrogen receptors (ERα/ERβ) to regulate gene transcription involved in reproductive and non-reproductive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, inducing secretory endometrium and inhibiting gonadotropin secretion.
| Metabolism | Estradiol: primarily hepatic via CYP3A4 and glucuronidation. Norethindrone acetate: extensively metabolized in the liver, primarily via reduction and subsequent glucuronidation or sulfation; Norethindrone acetate is a prodrug that is deacetylated to norethindrone, which is then hydroxylated by CYP3A4. |
| Excretion | Estradiol: primarily renal as metabolites (glucuronide and sulfate conjugates), ~90% in urine, ~10% in feces as bile. Norethindrone: urinary (50-70% as metabolites) and fecal (20-30%). |
| Half-life | Estradiol: terminal ~12-14 hours; norethindrone acetate: terminal ~8-11 hours. Steady-state reached within 5-7 days. |
| Protein binding | Estradiol: ~98% bound, mainly to sex hormone-binding globulin (SHBG) and albumin. Norethindrone: ~61% bound, primarily to albumin and SHBG. |
| Volume of Distribution | Estradiol: ~1.2 L/kg (extensive distribution). Norethindrone: ~3.8 L/kg (wide distribution). |
| Bioavailability | Oral estradiol: ~5-10% due to first-pass metabolism. Oral norethindrone: ~50-65% (first-pass but less extensive). |
| Onset of Action | Oral: endometrial effects within 2-3 days; transdermal: within 4-8 hours as steady estradiol levels. |
| Duration of Action | Oral: daily dosing maintains therapeutic levels for 24 hours; transdermal: patch worn for 7 days. |
1 tablet (estradiol 1 mg / norethindrone acetate 0.5 mg) orally once daily; adjust dose based on response and tolerability.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment recommended; use with caution in severe renal impairment (GFR <30 mL/min). |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C); for mild-moderate impairment (Child-Pugh A or B), use the lowest effective dose and monitor hepatic function. |
| Pediatric use | Not indicated in pediatric patients. |
| Geriatric use | Use the lowest effective dose for the shortest duration; increased risk of cardiovascular and thromboembolic events; consider non-hormonal alternatives. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CYP3A4 inducers can decrease efficacy Can cause thromboembolic disorders.
| FDA category | Positive |
| Breastfeeding | Excreted in human milk; may reduce milk production and quality. M/P ratio: estradiol ~0.5, norethindrone ~0.6. Use during breastfeeding not recommended. |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: potential for cardiovascular defects, limb reduction defects; exposure contraindicated. Second/third trimester: feminization of male fetus, urogenital sinus abnormalities, vaginal adenosis; avoid use. |
■ FDA Black Box Warning
Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported. In postmenopausal women with a uterus, unopposed estrogen increases the risk of endometrial cancer.
| Common Effects | abnormal uterine bleeding |
| Serious Effects |
Undiagnosed abnormal genital bleeding, known or suspected breast cancer (except in selected advanced cases), known or suspected estrogen-dependent neoplasia, active or past history of venous thromboembolism (e.g., DVT, PE), active or recent arterial thromboembolic disease (e.g., stroke, MI), known hepatic impairment or disease, known or suspected pregnancy, and known hypersensitivity to components.
| Precautions | Cardiovascular disorders (e.g., stroke, MI, thromboembolism), malignant neoplasms (e.g., breast cancer, endometrial cancer), dementia (increased risk in women >65 years), gallbladder disease, hypercalcemia, visual abnormalities, fluid retention, elevated triglycerides, and exacerbation of endometriosis. Lipid profile changes and possible glucose intolerance. |
Loading safety data…
| Fetal Monitoring | Pregnancy test before initiation; monitor fetal ultrasound if inadvertent exposure. Also monitor maternal blood pressure, blood glucose, liver function, and signs of thromboembolism. |
| Fertility Effects | Suppresses ovulation via negative feedback on gonadotropins. After discontinuation, return to fertility typically within 1-3 cycles; may cause temporary menstrual irregularities. |